REMARC

Comparaison d’un traitement d’entretien par Lenalidomide versus placebo chez des patients agés atteints d’un Lymphome Diffus à Grandes Cellules B (DLBCL) et répondeurs à un traitement d’induction par chimiothérapie de type R-CHOP (phase III)

REMARC Synopsis final

REMARC Synopsis Final

Suivi Long Terme

SLT

Publications 2022

Lysa 2022_LYSA_Deep Learning approach to automatize TMTV calculation regardless of segmentation methodology for main FDG avid lymphomas

Wendy Revailler, Anne-Ségolène Cottereau, Cédric Rossi, Rudy Noyelle, Thomas Trouillard, Franck Morschhauser, Rene-Olivier Casasnovas, Catherine Thieblemont, Steven Le Gouill, Marc P-E André, Hervé Ghesquières, Romain Ricci, Michel Meignan, Salim Kanoun

Diagnostics (Basel) . 2022 Feb 6;12(2):417. En savoir plus

Lysa 2022_LYSA_A guide to ComBat harmonization of imaging biomarkers in multicenter studies

Fanny Orlhac, Jakoba J. Eertink, Anne-Ségolène Cottereau, Josée M. Zijlstra, Catherine Thieblemont, Michel Meignan, Ronald Boellaard, Irène Buvat

J Nucl Med . 2022 Feb;63(2):172-179. En savoir plus

Lysa 2022_LYSA_A tumor volume and performance status model to predict outcome prior to treatment in diffuse large B-cell lymphoma

Catherine Thieblemont, Loic Chartier, Ulrich Duhrsen, Umberto Vitolo, Sally Barrington, Jan Zaucha, Laetitia Vercellino, Maria Gomes da Silva, Ines Patrocinio-Carvalho, Pierre Decazes, Pierre-Julien Viailly, Herve Tilly, Alina Berriolo-Riedinger, Olivier Casasnovas, Andreas Hüttmann, Hajira Ilyas, N. George Mikhaeel, Joel Dunn, Anne-Ségolène Cottereau, Christine Schmitz, Lale Kostakoglu, Joseph Paulson, Tina Nielsen, Michel Meignan

DOI: 10.1182/bloodadvances.2021006923 En savoir plus

Lysa 2022_LYSA_18F-FDG PET Maximum-Intensity Projections and Artificial Intelligence: A Win-Win Combination to Easily Measure Prognostic Biomarkers in DLBCL Patients

Kibrom B Girum, Louis Rebaud, Anne-Ségolène Cottereau, Michel Meignan, Jérôme Clerc, Laetitia Vercellino, Olivier Casasnovas, Franck Morschhauser, Catherine Thieblemont, Irène Buvat

DOI: 10.2967/jnumed.121.263501 En savoir plus

Publications 2021

Lysa 2021_LYSA_Incidence of central nervous system relapses in patients with DLBCL treated with lenalidomide as maintenance after R-CHOP

Sophie Bernard, Herve Ghesquieres, Rene-Olivier Casasnovas, Samuel Griolet, Maria Gomes da Silva, Pierre Feugier, Franck Morschhauser, Judith Trotman, Loic Renaud, Richard Greil, Alejandro Martin Garcia-Sancho, Sebastian Grosicki, Koen van Eygen, Christiane Copie-Bergman, Corinne Haioun, Catherine Thieblemont

Blood Adv . 2021 Aug 10;5(15):2965-2968. En savoir plus

Lysa 2021_LYSA_Deep-Learning 18F-FDG Uptake Classification Enables Total Metabolic Tumor Volume Estimation in Diffuse Large B-Cell Lymphoma

Nicolo Capobianco, Michel Meignan, Anne-Segolene Cottereau, Laetitia Vercellino, Ludovic Sibille, Bruce Spottiswoode, Sven Zuehlsdorff, Olivier Casasnovas, Catherine Thieblemont, and Irene Buvat

J Nucl Med . 2021 Jan;62(1):30-36. doi: 10.2967/jnumed.120.242412 En savoir plus

Lysa 2021_LYSA_New Approaches in Characterization of Lesions Dissemination in DLBCL Patients on Baseline PET/CT

Cottereau AS, Meignan M, Nioche C, Clerc J, Chartier L, Vercellino L, Casasnovas O, Thieblemont C, Buvat I.

Cancers (Basel) . 2021 Aug 8;13(16):3998. En savoir plus

Lysa 2021_LYSA_High-grade Follicular Lymphomas Exhibit Clinicopathologic, Cytogenetic, and Molecular Diversity Extending Beyond Grades 3A and 3B

Camille Laurent, José Adélaïde, Arnaud Guille, Bruno Tesson, Elodie Gat, Solene Evrard, Frederic Escudié, Charlotte Syrykh, Danielle Canioni, Bettina Fabiani, Véronique Meignin, Catherine Chassagne-Clement , Peggy Dartigues, Alexandra Traverse-Glehen, Marie Parrens, Sarah Huet, Christiane Copie-Bergman, Gilles Salles, Daniel Birnbaum, Pierre Brousset, Franck Morschhauser, Luc Xerri, Lymphoma Study Association (LYSA)

Am J Surg Pathol . 2021 Oct 1;45(10):1324-1336. En savoir plus

Publication 2020

Lysa 2020_LYSA_Risk stratification in diffuse large B cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET/CT

A S Cottereau, M Meignan, C Nioche, N Capobianco, J Clerc, L Chartier, L Vercellino, O Casasnovas, C Thieblemont, I Buvat

Ann Oncol . 2020 Dec 2;S0923-7534(20)43174-6. doi: 10.1016/j.annonc.2020.11.019. En savoir plus

Communication orale REMARC	ICMLugano 2021
Catherine Thieblemont	Defining ultra-high-risk DLBCL patients prior to initial treatment based on an integrative host and disease prognostic score (from REMARC study) ICMLugano Catherine Thieblemont Abstract N°017

Communication orale REMARC

ICMLugano 2021

Catherine Thieblemont

Defining ultra-high-risk DLBCL patients prior to initial treatment based on an integrative host and disease prognostic score (from REMARC study)

ICMLugano Catherine Thieblemont Abstract N°017

Posters REMARC	ICMLugano 2021
Catherine Thieblemont	Circulating tumor DNA load and total metabolic tumor volume in Diffuse Large B Cell Lymphoma (DLBCL) patients treated by R-CHOP – From REMARC, a LYSA study ICMLugano Catherine Thieblemont Abstract N°091
Catherine Thieblemont	High adipose tissue density is a negative prognostic factor in DLBCL patients treated by R-CHOP, independent from TMTV and PS – From the REMARC study ICMLugano Catherine Thieblemont Abstract N°166

Posters REMARC

ICMLugano 2021

Catherine Thieblemont

Circulating tumor DNA load and total metabolic tumor volume in Diffuse Large B Cell Lymphoma (DLBCL) patients treated by R-CHOP – From REMARC, a LYSA study

ICMLugano Catherine Thieblemont Abstract N°091

Catherine Thieblemont

High adipose tissue density is a negative prognostic factor in DLBCL patients treated by R-CHOP, independent from TMTV and PS – From the REMARC study

ICMLugano Catherine Thieblemont Abstract N°166